Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

EGFR

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands.

  • Tesevatinib
    TQ0166781613-23-8
    Tesevatinib (XL-647) is an orally available, multi-target tyrosine kinase inhibitor (IC50s: 0.3, 16, 1.5, 8.7, and 1.4 nM for EGFR, ErbB2, KDR, Flt4, and EphB4).
    • $109
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Cetuximab
    T9905205923-56-4
    Cetuximab (C225) is a monoclonal antibody that is an inhibitor of human epidermal growth factor receptor (EGFR) (Kd=0.201 nM). Cetuximab has antitumor activity, inhibiting tumor cell proliferation and inducing apoptosis.
    • $197
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • BLU-945
    T97542660250-10-0
    BLU-945 is a potent, highly selective, reversible, and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, effective against EGFR with L858R and/or exon 19 deletion mutations, T790M, and C797S mutations. It is utilized in lung cancer research, including non-small cell lung cancer (NSCLC).
    • $133
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Sunvozertinib
    T641242370013-12-8
    Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor and has inhibitory effects on EGFR, Her2 and mutant epidermal growth factor. Sunvozertinib showed inhibition of EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutation, and Her2 exon 20 YVMA and EGFR WT A431. IC50 were 20.4, 20.4, 1.1, 7.5 and 80.4 nM, respectively.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • TAS6417
    T169961661854-97-2
    TAS6417 is an EGFR inhibitor and is an efficacious drug candidate for patients with NSCLC (IC50: ranging from 1.1-8.0 nM).
    • $89
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Osimertinib
    T24901421373-65-0
    Osimertinib (AZD-9291) is an EGFR third-generation inhibitor that inhibits the T790M resistance mutation produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib has antitumor activity for the treatment of EGFR-mutated non-small-cell lung cancer.
    • $32
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Trastuzumab
    T9912180288-69-1
    Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.
    • $157
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Butein
    T6427487-52-5
    Butein (2’,3,4,4’-tetrahydroxy Chalcone), a plant polyphenol, is isolated from Rhus verniciflua. It can inhibit the activation of protein tyrosine kinase, NF-κB and STAT3, and also can inhibit EGFR.
    • $36
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • Sanguinarine chloride
    T01295578-73-4
    Sanguinarine chloride (Pseudochelerythrine chloride), a benzophenanthridine alkaloid, stimulates apoptosis by activating the production of reactive oxygen species (ROS).
    • $50
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Neratinib
    T2325698387-09-6
    Neratinib (HKI-272) (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor for HER2 and EGFR (IC50: 59/92 nM), respectively.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Cloperastine fendizoate
    T1361985187-37-7
    Cloperastine fendizoate (Hustazol) inhibits the hERG K+ currents in a concentration-dependent manner (IC50: 27 nM).
    • $42
    In Stock
    Size
    QTY
  • Lapatinib
    T0078231277-92-2
    Lapatinib (GW572016) is an inhibitor of ErbB2 and EGFR (IC50=9.2/10.8 nM) with oral activity. Lapatinib has antitumor activity and can be used to treat advanced or metastatic breast cancer with HER2 overexpression.
    • $29
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Tyrosine kinase-IN-7
    T77746345615-74-9
    Tyrosine kinase-IN-7 is a potent inhibitor of the tyrosine kinase EGFR, inhibiting EGFR(WT) and EGFR(T790M) and showing anti-cancer and anti-tumor activity in a variety of cancer cell lines. Tyrosine kinase-IN-7 has potential anti-inflammatory and antiviral activities.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • BI-4020
    T105342664214-60-0In house
    BI-4020 is a fourth-generation, orally active, and non-covalent inhibitor of EGFR tyrosine kinase. BI-4020 exhibits activity agains the triple mutant EGFR del19 T790M C797S variant (IC50=0.2 nM in BaF3 cell lines), the double mutant EGFR del19 T790M and primary mutant EGFR del19 (IC50=1 nM) and EGFR wt (IC50=190 nM). BI-4020 exhibits high kinome selectivity and good DMPK properties.
    • $288
    In Stock
    Size
    QTY
  • Erlotinib
    T0373183321-74-6
    Erlotinib (NSC-718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.
    • $40
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Genistein
    T1737446-72-0
    Genistein (NPI 031L) is an isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA TOPOISOMERASES, TYPE II), with antineoplastic and antitumor activities.
    • $38
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Gefitinib
    T1181184475-35-2
    Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.
    • $50
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • EGFR-IN-1 hydrochloride
    T11157L2227455-78-7In house
    EGFR-IN-1 hydrochloride is an irreversible and specific inhibitor of L858R/T790M mutant EGFR with 100-fold selectivity over wild-type EGFR. EGFR-IN-1 hydrochloride exhibits potent antitumor and antiproliferative activity in H1975 cells and the mutant HCC827 cells with IC50s of 4 and 28 nM, respectively.
    • $98
    In Stock
    Size
    QTY
  • AZD3759 hydrochloride
    T42491626387-81-2
    AZD3759 (hydrochloride) is an effective, orally active and central nervous system-penetrant EGFR inhibitor. At Km ATP concentrations, the IC50s are 0.2/0.3/0.2 nM for EGFR (L858R)/EGFR (wt)/EGFR (exon 19Del).
    • $37
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Tyrphostin 8
    T349733785-90-8
    Tyrphostin 8(4-Hydroxybenzylidenemalononitrile) is a potent GTPase inhibitor that inhibits EGFR kinase with an IC50 of 560 μM.Tyrphostin 8 inhibits protein serine/threonine calmodulin phosphatases (IC50=21 μM), enhances transferrin receptor-mediated transcytosis in Caco-2 cells, and increases the hypoglycemic effect of oral insulin-transferrin. hypoglycemic effect.
    • $31
    In Stock
    Size
    QTY
  • A-935142
    T140771031335-85-9In house
    A-935142 is a human ether-a-go-go-related gene (hERG, Kv 11.1) channel activator. a-935142 enhances hERG currents by slowing inactivation, promoting activation, reducing inactivation, shortening atrial and ventricular repolarization, and in a complex manner.
    • $350
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • WAY-270360
    T60064476633-98-4
    WAY-270360 (N-[4-(1H-benzimidazol-2-yl)phenyl]-2,4-dimethoxybenzamide) is a sirtuin modulator and an epidermal growth factor receptor (EGFR) inhibitor.
    • $58
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • AZD8931 diFuMaric acid
    T87511196531-39-1
    AZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC50 of 4 nM, 3 nM and 4 nM, respectively).
    • $133
    In Stock
    Size
    QTY
  • Epidermal Growth Factor
    T867962253-63-8
    Epidermal Growth Factor binds to epidermal growth factor receptor (EGFR) and stimulates cell growth and proliferation. It is approved for the treatment of diabetic foot ulcers.
    • $133
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • SYR127063
    T34760871026-18-5
    SYR127063 (BDBM-92454) (BDBM92454) is a potent and selective HER2 inhibitor, binds to HER2 in a reactive conformation.
    • $133
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • CP-380736
    T19814179688-29-0
    CP-380736 (PF-00520893) is an epidermal growth factor receptor (EGFR) inhibitor. EGFR is a tyrosine kinase that activates MAPK, JNK, and Akt pathways, and is an important mediator of several types of cancer.
    • $50
    In Stock
    Size
    QTY
  • Poziotinib hydrochloride
    T87581429757-68-5
    Poziotinib hydrochloride irreversibly inhibits EGFR (HER1 or ErbB1), including EGFR mutants, HER2, and HER4, thereby inhibiting the proliferation of tumor cells that overexpress these receptors. It is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor with potential antineoplastic activity.
    • $50
    In Stock
    Size
    QTY
  • Larotinib
    T733341438072-11-7
    Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.
    • $93
    In Stock
    Size
    QTY
  • BGB-102
    T10531807640-87-5
    BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3, which may be useful in the study of macular degeneration and diseases associated with genetic disorders and malformations.
    • $373
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Cavutilide
    T619131276186-19-6In house
    Cavutilide has antiarrhythmic activity, inhibits hERG K(+) channels, and can be used to study heart failure and persistent atrial fibrillation.
    • $293
    In Stock
    Size
    QTY
  • EGFR/ErbB-2 inhibitor-1
    T798611135150-79-6In house
    EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.
    • $195
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • AG-1557 hydrochloride (189290-58-2(free base))
    T4694
    AG-1557 hydrochloride is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase (pIC50: 8.194).
    • $33
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • AZ7550 hydrochloride
    T13564L2309762-40-9
    AZ7550 hydrochloride (AZ7550 hydrochloride ), an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).
    • $126
    In Stock
    Size
    QTY
  • EGFR-IN-3
    T63732
    EGFR-IN-3 is an EGFR inhibitor with potential antitumour activity.EGFR-IN-3 inhibits EGFRwt-TK and induces apoptosis (cell death), which can cause cells to block in the G2/M phase.
    • $397
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • EGFR-IN-5
    T111602225887-26-1
    EGFR-IN-5 is a selective inhibitor of EGFR. The IC50s for EGFR, EGFR(L858R), EGFR(L858R/T790M), and EGFR(L858R/T790M/C797S) are 10.4, 1.1, 34, 7.2 nM, respectively.
    • $108
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • EGFR-IN-99
    T359012068806-31-3
    EGFR-IN-99 (JBJ-03-142-02) is an EGFR and HER2 Exon 20 insertion mutation inhibitor with antiproliferative activity for the study of non-small cell lung cancer (NSCLC).
    • $129
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • DBPR112
    T109651226549-49-0In house
    DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM and 48 nM for EGFRWT and EGFRL858R/T790M, respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy.
    • $69
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • EGFR-IN-9
    T111631226549-39-8In house
    EGFR-IN-9 is a potent EGFR kinase inhibitor with IC50s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity.
    • $79
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • CGP77675
    T30855234772-64-6In house
    CGP77675 (ZINC1488120) is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and autophosphorylation of purified Src. CGP77675 exhibits anticancer activity.
    • $43
    In Stock
    Size
    QTY
  • CHMFL-EGFR-202
    T108022089381-40-6In house
    CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).
    • $117
    In Stock
    Size
    QTY
  • Epitinib succinate
    T359142252334-12-4In house
    Epitinib succinate (HMPL-813 succinate) is an orally active and brain penetration EGFR tyrosine kinase inhibitor and can be used in studies about cancer.
    • $69
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • SKLB 1028
    T346561350544-93-2In house
    SKLB 1028 (Ruserontinib) is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. SKLB 1028 shows excellent activity in FLT3-driven AML models and considerable potency in CML models containing Abl mutants.
    • $51
    In Stock
    Size
    QTY
  • CGP52411
    T10782145915-58-8In house
    CGP52411 is an orally active, and ATP-competitive inhibitor of EGFR (IC50: 0.3 μM). CGP52411 blocks the toxic influx of Ca2+ ions into neuronal cells and dramatically inhibits and reverses the formation of β-amyloid Aβ42 fibril aggregates. CGP52411 can be used in studies about Alzheimer's diseases.
    • $39
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • RTC-5
    T127771423077-49-9In house
    RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties. It exhibits considerable effectiveness against an EGFR-driven cancer xenograft model. The mechanism behind its efficacy can be attributed to the simultaneous inhibition of PI3K-AKT and RAS-ERK signaling pathways.
    • $48
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • ZM323881 hydrochloride
    T1991193000-39-4In house
    ZM323881 hydrochloride (ZM 323881 HCl) is a potent and selective VEGFR2 inhibitor.
    • $66
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • PF-06459988
    T164921428774-45-1In house
    PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor. PF-06459988 has high efficiency and high affinity for EGFRs double mutants containing T790M, and has minimal activity against WT EGFR. PF-06459988 makes a candidate drug for the treatment of cancer.
    • $149
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • PP1
    T6196172889-26-8
    PP1 (AGL 1872), a specific and effective Src inhibitor, is with IC50 for Lck/Fyn is 5 nM/ 6 nM, respectively.
    • $34
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Biochanin A
    T2859491-80-5
    Biochanin A (4-Methylgenistein) is an isoflavone derivative isolated from red clover Trifolium pratense with anticarcinogenic properties. Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Osimertinib mesylate
    T36341421373-66-1
    Osimertinib mesylate (Mereletinib mesylate) is an irreversible and mutant selective EGFR inhibitor (IC50s: 12/1 nM for EGFR(L858R) and EGFR(L858R/T790M)).
    • $45
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • RG13022
    T3545136831-48-6
    RG13022 (Tyrphostin RG13022) is a tyrosine kinase inhibitor; inhibits the autophosphorylation reaction of the EGF receptor (IC50: 4 μM).
    • $39
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
    TargetMol | Citations Cited